Pine Rest Virtual Grand Rounds “TAAR1: Science Behind a Potential New TAARget for Schizophrenia”

Presenter

• 

  LaGenia Bailey, Pharm.D., BCPP, C-IAYT

  Dr. LaGenia Bailey holds a Doctorate in Pharmacy and is Board Certified in Psychiatric Pharmacy. Her prior academic appointment was as a Clinical Associate Professor specializing in research and clinical practice for people with a diagnosis of Serious Mental Illness (SMI) at University of Illinois. She completed a residency and research fellowship at University of Missouri at Kansas City and at the Greater Kansas City Mental Health Foundation in the field of psychopharmacology. She has been on development teams for three new antipsychotics in the world. In her clinical practice she ran clinics for treatment resistant schizophrenia, clozapine clinic, dual diagnosis, movement disorders and a consult liaison team for psychiatrists for treatment resistant illness. A former residency director and investigator for the Schizophrenia research group, she taught at University of Illinois at the College of Medicine, Pharmacy, Nursing, Public Health and Social Work. Her career shifted to research and development due to a desire to be part of bringing new treatments to the world. She been part of the medical affairs teams at both Bristol-Myers Squibb and Sunovion Pharmaceuticals and has trained medical teams in Australia, Europe, US, Canada and Brazil on new molecular entities for psychosis and clinical aspects of disease state management and care. She is currently a Director, Medical Science Liaison for the Medical Affairs Research and Development division of Sunovion Pharmaceuticals in Psychiatry. Dr. Bailey has been a member of NAMI for 35 years and has lived experience of 4 family members with a diagnosis of Schizophrenia. Her mission is to decrease the suffering and empower recovery for all people with a diagnosis of SMI and their families.